Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Activated CIK + Anti-CD3-MUC1 in Advanced Kidney Cancer
NCT03540199Phase 2Withdrawn
- Sponsor
- Fuda Cancer Hospital
- Start
- Apr 2018
- Primary completion
- May 2020
- Modality
- Bispecific Antibodies, Cell Therapies
- Countries
- 1
01
Overview
A Phase 2 trial of Activated CIK + CD3-MUC1 bispecific antibody in kidney cancer, sponsored by Fuda Cancer Hospital. Planned start Apr 2018; status: withdrawn.
02
Drugs
Activated CIK + CD3-MUC1 bispecific antibody
03
Conditions
kidney cancer
Beyond the preview
Go deeper on NCT03540199.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03540199.